Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,090	2,488	2,730	3,106	2,886	2,194
Short-Term Investments	5,259	6,524	8,115	4,636	2,809	1,393
Cash & Short-Term Investments	8,349	9,013	10,845	7,742	5,695	3,587
Cash Growth	-20.63%	-16.90%	40.07%	35.96%	58.76%	11.59%
Accounts Receivable	5,326	5,844	5,299	5,023	5,059	3,112
Other Receivables	235	367.8	368.5	305.6	977.5	1,003
Receivables	5,561	6,212	5,667	5,329	6,037	4,115
Inventory	3,192	3,087	2,581	2,402	1,951	1,917
Prepaid Expenses	468.9	348.4	386.6	411.2	332.4	160.8
Restricted Cash	-	0.8	-	-	-	-
Total Current Assets	17,572	18,661	19,479	15,884	14,015	9,779
Property, Plant & Equipment	4,694	4,817	4,224	3,834	3,482	3,222
Long-Term Investments	9,593	9,060	5,471	6,640	6,878	3,195
Other Intangible Assets	1,167	1,149	1,039	915.5	6.7	-
Long-Term Deferred Tax Assets	3,443	3,314	2,575	1,724	876.9	858.9
Other Long-Term Assets	1,076	758.8	291.8	216.9	176.1	108.9
Total Assets	37,545	37,759	33,080	29,215	25,435	17,163
Accounts Payable	705.5	789.5	606.6	589.2	564	475.5
Accrued Expenses	2,242	2,497	2,339	2,054	1,593	1,609
Current Portion of Leases	-	30.3	19	12.4	719.7	-
Current Income Taxes Payable	-	-	-	-	326.3	19.5
Current Unearned Revenue	619.3	627.7	458.9	485.3	442	577.7
Other Current Liabilities	-	-	-	-	287.4	16.1
Total Current Liabilities	3,567	3,944	3,423	3,141	3,933	2,697
Long-Term Debt	1,985	1,984	1,983	1,981	1,980	1,979
Long-Term Leases	720	924.1	788.7	775.8	-	717.2
Long-Term Unearned Revenue	211.8	185.7	126.7	69.8	73.3	57.8
Other Long-Term Liabilities	1,674	1,367	785.4	582.2	680.2	687.1
Total Liabilities	8,158	8,406	7,107	6,551	6,666	6,138
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1
Additional Paid-In Capital	13,192	12,856	11,354	9,949	8,088	6,716
Retained Earnings	32,384	31,673	27,260	23,307	18,968	10,893
Treasury Stock	-16,218	-15,167	-12,560	-10,353	-8,261	-6,613
Comprehensive Income & Other	29.1	-7.9	-80.9	-238.8	-26.2	29.3
Shareholders' Equity	29,388	29,354	25,973	22,664	18,769	11,025
Total Liabilities & Equity	37,545	37,759	33,080	29,215	25,435	17,163
Total Debt	2,705	2,939	2,791	2,770	2,700	2,696
Net Cash (Debt)	14,921	14,974	13,451	11,565	9,833	4,027
Net Cash Growth	0.85%	11.32%	16.31%	17.61%	144.18%	-30.05%
Net Cash Per Share	130.74	130.09	118.30	101.89	87.64	34.99
Filing Date Shares Outstanding	105.67	107.02	107.46	106.73	106.44	104.14
Total Common Shares Outstanding	105.9	107.3	107.12	107	106.57	103.96
Working Capital	14,005	14,717	16,056	12,743	10,082	7,082
Book Value Per Share	277.50	273.57	242.47	211.81	176.11	106.05
Tangible Book Value	28,221	28,205	24,935	21,749	18,762	11,025
Tangible Book Value Per Share	266.48	262.86	232.78	203.26	176.05	106.05
Land	-	288.2	283.1	264.5	248	241.2
Buildings	-	2,573	2,423	2,270	2,089	1,891
Machinery	-	2,149	1,940	1,803	1,662	1,395
Construction In Progress	-	1,722	1,345	980.5	767.7	724.5
Leasehold Improvements	-	154.5	133.9	114.3	113.9	100.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.